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Abstract
Background
Trachoma is a progressive blinding disease initiated by infection of the conjunctiva with
Chlamydia trachomatis. Repeated infections are thought to cause chronic inflammation,
which drives scarring, leading to in-turning of the eyelids. The relationship between C. tra-
chomatis, clinical inflammation and scarring development in children is not fully understood
due to a paucity of longitudinal studies with infection data at frequent follow-up.
Methods and findings
This longitudinal cohort study took place in northern Tanzania. Children aged 6–10 years at
baseline were eligible for inclusion. Participants were visited every three months for four
years. Clinical signs and conjunctival swabs for C. trachomatis detection by qPCR were col-
lected at each time-point. Conjunctival photographs from baseline and final time-points
were graded and compared side-by-side to determine scarring incidence and progression.
Of the 666 children enrolled in the study, outcome data were obtained for 448. Scarring
progression was detected in 103/448 (23%) children; 48 (11%) of which had incident scar-
ring and 55 (12%) had progression of existing scarring. Scarring was strongly associated
with increasing episodes of trachomatous papillary inflammation (TP). Weaker associations
were found between episodes of C. trachomatis infection and follicular trachoma (TF) with
scarring progression in unadjusted models, which were absent in multivariable analysis
after adjusting for inflammation (multivariable results: C. trachomatis p = 0.44, TF p = 0.25,
TP p = <0.0001, age p = 0.13, female sex p = 0.05). Individuals having TP at 30% or more of
the time-points they were seen had an odds ratio of 7.5 (95%CI = 2.7–20.8) for scarring pro-
gression relative to individuals without any TP detected during the study period.
Conclusions
These data suggest that the effect of infection on scarring progression is mediated through
papillary inflammation, and that other factors contributing to the development of
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inflammation, in addition to C. trachomatis infection, may be important in driving conjunctival
scarring progression in children. The addition of TP as a measure in trachoma control pro-
grams would provide an indication of the future risk of developing scarring sequelae.
Author summary
Trachoma is the leading cause of preventable blindness worldwide and is targeted for
elimination as a public health problem by 2020. The natural history of trachoma is not
completely understood however. We conducted a four-year longitudinal study in a tra-
choma-endemic area of northern Tanzania with detailed follow up every three months. In
the four-year study period, nearly one quarter of children developed progression of con-
junctival scarring, despite three rounds of annual mass drug administration (MDA) for
trachoma control. Disease progression was strongly associated with increasing proportion
of episodes with conjunctival papillary inflammation (TP), and only weakly associated
with Chlamydia trachomatis infection and trachomatous inflammation–follicular (TF).
Analysis revealed that associations between infection and TF with scarring progression
were mediated through TP, and that other factors causing individual differences in TP
were also contributing to scarring progression. These data have significant implications
for trachoma control. We hypothesise that in individuals who have previously experienced
ocular C. trachomatis infection, TP is the primary driver of scarring progression. The
addition of TP to trachoma surveillance programs would provide an indicator for active
disease progression in the community and a more accurate guide to the need for future
trichiasis interventions.
Introduction
Sight loss from trachoma, the leading infectious cause of blindness, is the end result of an
inflammatory-scarring process. Starting from early childhood, people growing-up in a tra-
choma endemic community may be repeatedly exposed to ocular challenge with Chlamydia tra-
chomatis, the causative organism. This is thought to trigger inflammatory responses that lead to
conjunctival scarring in some individuals[1]. As a result of conjunctival scarring the eyelids
(entropion) and eyelashes (trichiasis) turn in, scratching the ocular surface and resulting in cor-
neal opacification[1]. These complications of scarring usually develop during adulthood.
Trachoma control rests on the SAFE Strategy: Surgery for trichiasis, Antibiotic treatment
to treat C. trachomatis infection, Facial cleanliness and Environmental improvements to
reduce transmission. Endemic countries and the international community have set the ambi-
tious target of 2020 for the elimination of trachoma as a public health problem[2]. There is no
specific treatment to halt the progression of scarring, beyond controlling the infection.
Around 3.2 million people are estimated to have trichiasis and 1.9 million of these are blind
or have severe visual impairment[3]. Currently WHO estimates that 158 million people live in
districts that require A, F and E interventions[4]. Nearly 90% of these people live in Sub-Saha-
ran Africa.
Longitudinal data sets documenting the incidence or progression of conjunctival scarring
trachoma are limited[1]. Such studies are complex and can take many years to complete. In this
paper we report the clinical signs and infection results of children who were followed up every
three months for four years. The aim of the study was to investigate the risk factors associated
Progressive scarring trachoma in children
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with scarring incidence and progression in Tanzanian children. We investigated the association
between scarring progression and clinical signs of inflammation, C. trachomatis infection, age
and sex, in order to strengthen the evidence base that supports trachoma control programs.
Methods
Ethical statement
This study was reviewed and approved by Ethics Committees of the Tanzania National Insti-
tute for Medical Research, Kilimanjaro Christian Medical University College and the London
School of Hygiene & Tropical Medicine. It adhered to the tenets of the Declaration of Helsinki.
The study was explained in detail in Kiswahili or Maasai; written informed consent from a par-
ent or legal guardian was necessary for enrollment.
Study design and population
We recruited a cohort of children from three neighboring villages in northern Tanzania. Two
villages were in Siha district located in Kilimanjaro region and one was in Longido district
located in Arusha region. They were assessed every three months for four years, totaling 17
time-points. The communities and recruitment have been previously described in detail[5].
These communities are predominantly comprised of Maasai people. Children aged between 6
and 10 years at baseline (February 2012), who were normally resident in the villages, were eli-
gible for inclusion. This restricted age group was chosen as we anticipated that younger chil-
dren may not have manifest incident / progressive conjunctival scarring during the four years
of follow-up. A census was conducted and eligible children enrolled.
Clinical assessment and sample collection
At each time-point all available children were examined by an experienced ophthalmic nurse.
The eye was first anaesthetized with preservative-free proxymetacaine hydrochloride 0.5% eye-
drops. The left upper eyelid was everted and tarsal conjunctiva examined (using x2.5 loupes
and torch) for signs of trachoma and graded using the 1981 WHO ‘FPC’ detailed grading sys-
tem[6]. This grading system corresponds to the WHO Simplified Trachoma Grading System:
F2/F3 equates to Trachomatous Inflammation-Follicular (TF), and P3 to Trachomatous Inflam-
mation-Intense (TI)[7]. “Clinically Active Trachoma” was defined as presence of TF and/or TI.
We also consider that both P2 and P3 represent clinically significant papillary inflammation,
and refer to this as “TP”[8]. High resolution photographs (Nikon D90 camera with 105mm
Macro lens) were taken of the conjunctiva for independent grading.
Two conjunctival swab samples were collected (Dacron polyester, Puritan Medical Products
Company, Maine) at each time-point. The first was placed in RNAlater (Thermo Fisher, UK)
and the second was stored dry. Clinical swabs and air control swabs were collected and stored
as described previously[5]. Samples were stored on ice in the field and were transferred to a
-80˚C freezer upon return to the laboratory later the same day.
Trachoma control
Following approval from the Ministry of Health (MoH) and in collaboration with the district
eye coordinators the SAFE strategy was implemented in study villages by the study field team.
Education was provided regarding facial cleanliness and environmental improvements and
free trichiasis surgery was offered. Azithromycin mass drug administration (MDA) was
administered by the study team, according to WHO guidelines, in August 2012, August 2013
and August 2014. In mid-2015, one of the three villages from Longido district, which had a
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persistently elevated TF prevalence, received a further round of MDA. This was delivered by
the local MoH team as part of the district-wide distribution. The other two villages, which are
in the neighboring district (Siha), were not re-treated as the district-wide prevalence was
below the treatment indication threshold, and these two villages had shown a good response to
the three rounds of MDA.
Chlamydia trachomatis detection
At the first time-point, DNA was extracted using the PowerSoil DNA Isolation Kit (Mo Bio
Laboratories, USA) from swab samples stored in dry tubes and C. trachomatis was detected by
droplet digital PCR, as previously described[5, 9]. At all subsequent time-points, DNA was
extracted from samples stored in RNAlater using the Norgen RNA/DNA purification kit (Nor-
gen Biotek) and C. trachomatis was detected by triplex quantitative PCR (qPCR) for chlamyd-
ial chromosomal (omcB) and plasmid (pORF2) genes and a human endogenous control gene
(RPP30), as described previously[10]. Time-point 2 Norgen-extracted samples were tested by
both detection methods and the kappa score for agreement was 0.84. Samples were tested in
duplicate and were defined as C. trachomatis positive if RPP30 and pORF2 and/or omcB ampli-
fied in <40 cycles in one or both replicates.
Analysis
We used photographic grading to determine whether there was either development of incident
scarring in previously un-scarred conjunctiva, or increase in pre-existing scarring. Conjunctival
photographs from baseline (time-point 1) were compared to the final time-point (time-point
17). For individuals not seen at time-point 1, the image from time-point 2 was used for their
baseline. Similarly, if an individual was not seen at time-point 17, the image from time-point 16
was used as their final time-point. The images were assessed by an ophthalmologist experienced
in using a detailed scarring grading system[11]. Baseline and final photographs were compared
side-by-side to produce the main binary outcome variable of overall “scarring progression”,
defined as evidence of either incident scarring or worsening of pre-existing scarring. For further
sub-analyses, we subdivided individuals with “no scarring progression” into (1) no scarring at
either baseline and final; (2) scarring unchanged between baseline and final. We subdivided
individuals with “scarring progression” into (3) incident scarring (no scarring at baseline and
new scarring at final); (4) increasing scarring (some scarring at baseline and more at final).
All field data were managed in Access (Microsoft). Data were merged and analyzed in
STATA v14. The total number of time-points at which participants were seen varied due to
absence or refusal. We excluded from the analysis individuals who were seen on fewer than
four occasions or did not have outcome data (time-point 16 or 17 assessments). A proportion
variable was generated for each of TF, TP and C. trachomatis infection: number of time-points
with each factor as a proportion of the total number of time-points that individual was seen.
Proportions were subsequently categorized.
Separate mixed effects logistic regression models were used to determine the association
between (1) TP, (2) TF, and (3) C. trachomatis infection with sex and baseline age, using data
from all time-points in the longitudinal dataset. Mixed effects regression was also performed
to assess the relationship between (1) TF and C. trachomatis infection, and (2) TP and C. tra-
chomatis, again using data from all time-points in the longitudinal dataset (adjusting for age at
baseline and sex). These analyses were limited to the 448 individuals with outcome data.
To identify risk factors for scarring progression, analysis was initially performed using
logistic regression to assess the association between categorized proportions of TF, TP or C.
trachomatis infection and overall scarring progression (either incident scarring in those
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without scarring at baseline or progression of pre-existing scarring). Each of these were ini-
tially included as exposures separately in a logistic regression using scarring progression as the
outcome variable and adjusting for age at baseline and sex. Following this, all three were
included in a final multivariable model (adjusting for baseline age and sex), and likelihood
ratio tests were performed between models including versus excluding each exposure to deter-
mine its overall P value. The analyses were subsequently repeated to identify risk factors for
incident scarring and progression of pre-existing scarring separately. In the first set of univari-
able and multivariable analyses (using the same exposures as above) the analysis was restricted
to individuals without scarring at baseline (incident scarring versus no scarring). In the second
set, analysis was restricted to individuals with scarring at baseline (progression of existing scar-
ring versus no progression of existing scarring).
Chlamydial load was calculated by extrapolating from a standard curve. OmcB in copies/μl
was log10 transformed to normalize the distribution. In the longitudinal dataset random
effects linear regressions were performed to look for associations between a) chlamydial load
and scarring progression (adjusting for MDA-period, age at baseline and sex), and b) chla-
mydial load and age at time-point (in years) in C. trachomatis positive individuals (adjusting
for sex and MDA-period). Age at time-point was split into four groups; <7.5 years,�7.5 -<10
years,�10 -<12.5 years, and�12.5 years. A random effects linear regression was then per-
formed to assess for association between chlamydial load, age group and progression, includ-
ing an interaction term between age group and progression in order to determine whether the
association between chlamydial load and progression was modified by age. MDA-period (pre-
MDA, post first MDA, post second MDA, post third MDA) was included in the model to
adjust for confounding.
Results
Study participants
The participant flow is shown in Fig 1. There were 666 potentially eligible children and 616
enrolled. Fifty either refused or were absent. We excluded 57 who were examined on less than
four occasions, and 111 without scarring progression outcome data (no time-point 16 or 17
assessment). This left 448 in this analysis, who were seen at a median of 15 time-points (1st–
3rd quartiles = 13–16, S1 Fig).
The demographic characteristics of the entire cohort were described in the baseline report
[5]. Of the 448 children included in this analysis, 242 (54.0%) were female, mean age at base-
line was 6.8 years, and 438 (97.8%) were Maasai. Of the 218 children not included, 92 (42.2%)
were female (OR = 1.61, 95%CI = 1.16–2.23, p = 0.004), mean age at baseline was 7.4 years
(OR = 0.86, 95% CI = 0.79–0.93, p<0.0002) and 214 (98.2%) were Maasai. Younger children
and females were therefore more likely to be included in this study analysis.
Antibiotic coverage of the 448 children included in scarring progression analysis was 355
(79.2%) in 2012, 374 (83.5%) in 2013 and 338 (75.4%) in 2014. The estimated community-
wide MDA coverage in 2012, 2013 and 2014 were 68.7%, 42.9% and 72.9%, respectively.
Clinical disease
Of the 448 participants, 240 (53.6%) had TF (F2/F3), 185 (41.3%) had TP (P2/P3)), and 248
(55.4%) had clinically active trachoma (F2/3 and/or P3) at one or more time-point. The preva-
lence of TF and TP is shown for each time-point in Fig 2.
There was a significant reduction in inflammatory disease following MDA, although TP
prevalence was particularly high at time-point 6. Examination of inflammation and infection
prevalence by village revealed that this peak in TP was found in only two of the three villages
Progressive scarring trachoma in children
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Fig 1. Flow chart for eligible study participants. The chart shows the number of individuals enrolled, excluded and
included in the analysis of scarring progression.
https://doi.org/10.1371/journal.pntd.0007638.g001
Fig 2. The prevalence of C. trachomatis infection and clinical signs at each time-point. Data are shown for the 448 individuals with outcome data.
There were three-month intervals between time-points. Red vertical lines indicate annual MDA treatment given to all three study villages. The red
dashed vertical line indicates treatment given to one village with residual disease.
https://doi.org/10.1371/journal.pntd.0007638.g002
Progressive scarring trachoma in children
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(“A” and “C”), and did not appear to correlate with infection (S2 Fig), indicating that it may
have been driven by non-chlamydial infection.
The number of individuals with categorized proportions of time-points (none, <10%, 10–
19%, 20–29%, 30%+) that they were found to have (1) TF, (2) TP and (3) C. trachomatis infec-
tion is shown in Table 1. At baseline, 93 (20.8%) had some degree of conjunctival scarring.
The odds of TF were estimated to be higher in females (OR = 1.49, 95%CI = 1.05–2.11,
P = 0.025) and lower with each additional year of age (OR = 0.65, 95%CI = 0.59–0.71,
p<0.0001) in the longitudinal dataset. The odds of TP were also estimated to reduce with age
(OR = 0.79, 95%CI = 0.71–0.88, p<0.0001) but the evidence of an association with sex was
much weaker (OR = 1.39, 95%CI = 0.92–2.09, p = 0.119). There was little difference between
children included and those excluded in the analysis in terms of sex and baseline TF/TP/infec-
tion although those excluded tended to be slightly older on average than those included (mean
baseline age 7.4 vs 6.8, p<0.001).
C. trachomatis infection
C. trachomatis was detected in 219/448 (48.9%) at one or more time-points. The prevalence of
infection is shown for each time-point in Fig 2. The proportion of time-points that each indi-
vidual had infection is shown in Table 1. The median proportion of time-points infected
among the 219 individuals who had C. trachomatis detected on at least one occasion was
12.5%, which was equivalent to ~2 time-points if someone had been seen on all 17 visits.
Infection prevalence declined following each round of MDA, however at time point 10 (9
months after second MDA) it had increased and at time-point 14 (9 months after third MDA)
infection prevalence had returned to pre-MDA levels (10–15%). Infection prevalence dropped
again by time-points 16 and 17. Further examination of infection and clinical sign prevalence
in each of the three villages showed that the majority of infection and TF at later time-points
were found in only village “C” (S2 Fig). Village “C” is located in a different administrative dis-
trict, which (unlike the other two villages) was eligible for and received MoH administered
MDA treatment in July-2015. This was subsequently followed by a further drop in infection,
TF and TP prevalence in village “C” at time-points 16 and 17 (S2 Fig).
In a mixed effects logistic regression of infection at any time-point, female sex (OR = 1.7,
95%CI = 1.25–2.34, p = 0.001) and younger baseline age (OR = 0.82, 95%CI = 0.75–0.99,
p<0.0001) were significantly associated with C. trachomatis infection.
Clinical disease and infection
Overall, there was a strong association between C. trachomatis infection and TF (OR = 11.6,
95%CI = 8.9–15.0, P<0.0001) and TP (OR = 9.6, 95%CI = 7.1–12.8, P<0.0001) in the longitu-
dinal dataset (adjusted for baseline age and sex). The odds ratios for TP and TF as predictors
Table 1. Number of individuals with C. trachomatis infection, TF and TP, categorized by proportion of time-points. C. trachomatis infection, TF and TP were
detected as a percentage of the total number of time-points that individual was seen.
Proportion of time-points C. trachomatis TF TP
n (%) n (%) n (%)
None 229 (51.1%) 208 (46.4%) 263 (58.7%)
<10% 78 (17.5%) 52 (11.6%) 71 (15.8%)
10–19% 79 (17.6%) 71 (15.9%) 48 (10.7%)
20–29% 43 (9.6%) 56 (12.5%) 41 (9.2%)
30% + 19 (4.2%) 61 (13.6%) 25 (5.6%)
https://doi.org/10.1371/journal.pntd.0007638.t001
Progressive scarring trachoma in children
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007638 August 14, 2019 7 / 16
of C. trachomatis infection (adjusted for TP/TF, age at baseline and sex) at each time-point
were generally similar to or slightly higher after the initiation of MDA, however confidence
intervals were much wider (S3 Fig).
Scarring progression
Overall, scarring progression was observed in 103/448 (23.0%) participants (Table 2). There
were 307 (68.5%) who had no scarring; 38 (8.5%) with unchanged scarring; 48 (10.7%) with
incident scarring; and 55 (12.3%) with increasing scarring.
The relationships between scarring progression and proportion of time-points when C. tra-
chomatis was detected or signs of inflammation (TF or TP) were seen, adjusting only for age at
baseline and sex, are shown in Table 3. In these models strong evidence was found of an associ-
ation between progression and both TP and TF, but the association between infection and pro-
gression was weaker. There was also evidence of a greater risk of progression in females
compared to males.
In a multivariable model (Table 4) for scarring progression (retaining infection, TF, TP, age
at baseline and sex), the strong relationship between increasing proportion of time-points with
TP and scarring progression remained. Female sex was marginally associated. There was no
association with either TF or infection, suggesting that the associations between TF and infec-
tion with scarring were mediated through TP.
The analysis was repeated, restricted to individuals with (a) no scarring at baseline, and (b)
some scarring at baseline, in order to differentiate between factors associated with incident
scarring and progression of pre-existing scarring, respectively. In the unadjusted models there
was evidence for associations between episodes of C. trachomatis infection, TF and TP and
incident scarring (S1 Table). In the multivariable model however, only TP was significantly
associated with incident scarring, again suggesting that the effect of infection and TF was
mediated through TP (S2 Table). Neither infection, TF nor TP were significantly associated
with progression of pre-existing scarring in either the unadjusted or adjusted models. There
seemed to be a trend for increasing risk of progressive scarring with increasing episodes of TP,
however the evidence for this effect was weak, it should be noted that the sample size for these
sub-analyses was small. These data from children with pre-existing scarring did not demon-
strate that additional episodes of C. trachomatis infection were associated with further progres-
sion of scarring. Female sex was associated with an increase in pre-existing scarring but not
with incident scarring. There were no associations with age.
C. trachomatis infection load
Bacterial load in C. trachomatis positive individuals was equivalent between people with and
without scarring progression, using data from all time-points (adjusting for age at baseline, sex
Table 2. Scarring progression category by presence of C. trachomatis infection and clinical features. Both infection and clinical features were detected at one or more
time-points.
Overall scarring Scarring subgroups
Clinical phenotype Total Progression No progression No scarring Unchanged scarring Incident scarring Increasing scarring
Total 448 103 (23%) 345 (77%) 291 (65%) 54 (12%) 48 (10.7%) 55 (12.3%)
No infection/TP/TF 122 17 (13.9%) 105 (86.1%) 95 (77.9%) 10 (8.2%) 11 (9%) 6 (4.9%)
Any TF 240 67 (27.9%) 173 (72.1%) 136 (56.7%) 37 (15.4%) 31 (12.9%) 36 (15%)
Any TP 185 67 (36.2%) 118 (63.8%) 89 (48.1%) 29 (15.7%) 28 (15.1%) 39 (21.1%)
Any C. trachomatis 219 55 (25.1%) 164 (74.9%) 137 (62.6%) 27 (12.3%) 29 (13.2%) 26 (11.9%)
https://doi.org/10.1371/journal.pntd.0007638.t002
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and pre/post-MDA period) (OR = 1.1, 95% CI = 0.86–1.42, p = 0.45). There was evidence of
an association between age at time-point (in years) and infection load among C. trachomatis
positive individuals, with lower loads in older individuals (OR = 0.91, 95%CI = 0.86–0.97,
p = 0.004), adjusting for sex and MDA period. Bacterial load in C. trachomatis positive pro-
gressors and non-progressors was plotted across different age groups (derived from age in
years at that time-point) to determine whether the association between scarring progression
and load varied by age. In the oldest age group, progressors had a slightly higher infection load
relative to non-progressors, Fig 3, which was supported by evidence for an interaction between
age group and progression in their association with bacterial load (p = 0.012). The model
including the interaction explained the data better than the model without the interaction
(p = 0.016).
Discussion
The development of trachomatous scarring is probably the result of a complex interaction
between C. trachomatis infection, variation in the host immune response and possibly other
pro-inflammatory stimuli. However, long-term data exploring the relative contributions of
these factors to the development of scarring in children are limited.
In this cohort of Tanzanian children aged 6–10 years old at baseline we found that 23% had
trachomatous scarring progression over the course of four years. Roughly half of this was new
scarring whilst the other half involved progression of pre-existing scarring. Scarring progres-
sion was strongly associated with increasing frequency of conjunctival papillary inflammation
(TP). This suggests that controlling TP could potentially limit progressive scarring trachoma.
Table 3. Univariable logistic regression models of the associations between overall scarring progression and C. trachomatis infection and clinical features. C. tracho-
matis infection, TF and TP were categorized by proportions of time-points present, and were adjusted only for age at baseline and sex. The overall P value for each model
is shown in line with the variable name.
n/N (%) OR 95% CI P value
C. trachomatis 0.041
None 48/229 (20.9%)
<10% 12/78 (15.4%) 0.64 0.3–1.3
10–19% 21/79 (26.6%) 1.29 0.7–2.4
20–29% 15/43 (34.9%) 1.91 0.9–3.9
30% + 7/19 (36.8%) 2.20 0.8–6.0
TF 0.0004
None 36/208 (17.3%)
<10% 8/52 (15.4%) 0.93 0.4–2.2
10–19% 18/71 (25.4%) 1.96 1.0–3.9
20–29% 15/56 (26.8%) 1.92 0.9–4.0
30% + 26/61 (42.6%) 4.41 2.2–8.8
TP <0.0001
None 36/263 (13.7%)
<10% 17/71 (23.9%) 2.14 1.1–4.2
10–19% 15/48 (31.3%) 3.08 1.5–6.4
20–29% 21/41 (51.2%) 7.26 3.5–15.0
30% + 14/25 (56.0%) 8.41 3.5–20.2
Age at baseline 1.01 0.9–1.1 0.853
Sex
Male
Female
38/206
65/242
(18.5%)
(26.9%)
1.62 1.0–2.6 0.036
https://doi.org/10.1371/journal.pntd.0007638.t003
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We found only weak evidence of an association between C. trachomatis infection and scar-
ring progression. Increasing proportions of infection episodes were associated with incident
scarring, however, multivariable analysis showed that this effect was mediated through TP.
These data suggest that other factors, in addition to C. trachomatis infection, are important
determinants of the development of TP and progression of scarring. The data also indicate
that the clinical sign of TF has no association with scarring progression after adjusting for TP,
suggesting that TF is not a direct cause of, nor the best prognostic marker for scarring progres-
sion. For this purpose, TP prevalence might be a more informative clinical marker, and control
programs could consider using TF in combination with TP prevalence to predict future risk of
scarring.
Our finding that increasing frequency of papillary inflammation is strongly associated with
scarring progression has consistently been reported by other studies[1], however the relation-
ship between chlamydial infection and scarring progression is less definitive.
The first longitudinal study to try to investigate scarring progression was conducted by
Dawson et al in Tunisia, starting in the late 1960’s. They examined a group of children and
younger adults (n = 213) on two occasions about 14 years apart; no tests for C. trachomatis
infection were performed. TI (P3) was the strongest risk factor for developing severe scarring
(RR = 18), whilst TF had a weaker association (RR = 2.8)[12]. Interestingly, there also appeared
to be increased scarring risk associated with moderate papillary inflammation (P2).
West et al investigated the relationship between “constant severe inflammatory trachoma”
(TI diagnosed at more than half of the examinations) in a group of children (n = 190) exam-
ined on four occasions during the baseline year and once again at 7 years[13]. TI was
Table 4. Multivariable logistic regression model for the association between overall scarring progression and C.
trachomatis infection and clinical features. Categorized proportions of time-points with C. trachomatis infection, TF
and TP were included, adjusting for age at baseline and sex. The overall P value for each variable is shown in line with
the variable name, derived from a likelihood ratio test of the model including versus excluding that variable.
OR 95% CI P value
C. trachomatis 0.4396
None
<10% 0.49 0.2–1.1
10–19% 0.90 0.5–1.8
20–29% 0.80 0.3–1.9
30% + 0.72 0.2–2.5
TF 0.2535
None
<10% 0.85 0.3–2.1
10–19% 1.07 0.5–2.3
20–29% 0.84 0.3–2.0
30% + 2.09 0.9–5.0
TP <0.0001
None
<10% 2.19 1.1–4.4
10–19% 2.94 1.3–6.7
20–29% 6.67 3.0–14.9
30% + 7.48 2.7–20.8
Age at baseline 1.11 1.0–1.3 0.128
Sex (Female) 1.65 1.0–2.7 0.051
https://doi.org/10.1371/journal.pntd.0007638.t004
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associated with increased risk of developing scarring by 7 years. TF alone was not associated
with development of scarring.
Only one study, by Wolle et al, has previously examined the relationship between C. tracho-
matis infection and the subsequent development of scarring in children[14]. They reported a
five-year cohort of Tanzanian children (n = 189) that were examined on five occasions during
the first 18 months and once again at 5 years. They found that incident scarring over the five
years was associated with constant inflammation and/or constant C. trachomatis infection dur-
ing the first 18 months (OR 5.74, 95%CI 2.39–13.8). However, the effects of infection and
inflammation were not modelled independently of each other, possibly due to sample size lim-
itations, therefore, the independent contribution from infection remained unclear.
Burton et al found a strong association between progression of pre-existing scarring in
adults and increasing episodes of papillary inflammation (P2/P3) in Ethiopia (n = 585; OR
5.93, 95%CI 3.31–10.6, p<0.0001) and Tanzania (n = 577; OR 5.76, 95%CI 2.60–12.7,
p<0.0001)[8]. The study examined and sampled participants on a 6-monthly basis for two
years. Episodes of C. trachomatis infection were very infrequent, and they were not associated
with disease progression.
Our finding that C. trachomatis infection was marginally associated with incident scarring
(before adjustment) but not with progressive scarring is consistent with chlamydial infection
being important for initiating the scarring disease process. However, once scarring is estab-
lished, other factors driving TP are perhaps increasingly important for scarring progression.
However, an alternative but perhaps less likely explanation for this finding might be that peo-
ple who are more innately predisposed to developing scarring clear infection episodes rapidly
Fig 3. Distribution of omcB load in scarring progressors and non-progressors, split by age group at time-point.
https://doi.org/10.1371/journal.pntd.0007638.g003
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(which are therefore not readily detected), but also experience more severe and prolonged
inflammation (TP) in the aftermath[15, 16]. Our analysis of progression of pre-existing scar-
ring was also limited by a smaller sample size.
Conjunctival inflammation may be associated with other bacterial or viral infections, or
with allergic conjunctivitis[17, 18]. Several cross-sectional studies have found associations
between non-chlamydial ocular bacterial infections and active trachoma (TF/TP), conjunctival
scarring, trichiasis/recurrent trichiasis and corneal scarring[11, 19–24]. A recent longitudinal
study in 452 Tanzanian adults found that ocular commensal and pathogenic non-chlamydial
bacterial infections were more common in scarring progressors relative to non-progressors
and that, after adjusting for other factors, ocular infections were marginally associated with
scarring progression at two years[25].
C. trachomatis infection might damage the barrier function or homeostasis of the conjunc-
tival epithelium, such that external stimuli cause inflammation where they would not have
done otherwise. The expression of mucins has consistently been found to be dysregulated in
active and scarring trachoma, supporting this hypothesis[5, 26]. Long-term exposure to cook-
ing smoke has also been linked to conjunctival inflammation[27], particularly affecting
women, however a Tanzanian longitudinal study did not find any association between expo-
sure to cooking fires and incident scarring[28]. Use of traditional medicines might also have a
role, as could differences in diet or coinfections that lead to variation in host immune
responses.
Genetic or epigenetic factors might also contribute to differences in host inflammatory
responses. Several studies have reported associations between genetic differences and risk of
trachoma, including one genome-wide association study[29–35]. Further detailed investiga-
tions of ocular microbial infections and host genetics are required to establish their roles in
this disease.
There was a marginal association between female sex and overall scarring progression. Fur-
ther analysis revealed that female sex was associated with progression of pre-existing scarring
but not with incident scarring (S1 Table). Female sex was also associated with C. trachomatis
infection, TF and only very marginally with TP. These findings are difficult to reconcile, as
there were associations between infection and incident scarring, and between infection and
female sex. Whereas, there was no association between infection and progressive scarring and
only a marginal association between TP and female sex. Our findings also contrast those of
previous longitudinal studies in which female sex was associated with scarring incidence but
not progression[1]. The numbers in our analysis of pre-existing scarring were relatively small,
therefore sample size limitations might explain these findings. Nevertheless, overall females
were at greater risk of overall scarring progression, after adjustment for C. trachomatis infec-
tion and TP, suggesting that this effect was mediated by another mechanism.
We found no association between age and scarring progression, which may be due to the
limited four year age range of our study participants. Age was strongly associated with C. tra-
chomatis infection, TF and TP, all of which were more common in younger participants, per-
haps suggesting that some level of acquired protective immunity develops. There was some
evidence that in the oldest age group, scarring progressors had a higher chlamydial load rela-
tive to non-progressors, perhaps suggesting that their immunological control of the infection
was less effective, although this evidence was very weak.
A strong association was seen between infection and TF or TP. In contrast to previous
reports the association did not diminish after MDA[36], however C. trachomatis infection was
still relatively common and the effect estimates had very wide confidence intervals. Infection
prevalence recovered after MDA to near pre-MDA levels, whereas TP and TF prevalence
remained low post-MDA. Most of the residual disease and infection was concentrated in
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village “C”, which lies within a district with historically higher levels of endemic trachoma. A
study from central Tanzania has shown a significant reduction of both C. trachomatis infection
and TF after each of three annual rounds of MDA in children aged 1 year and above, where
MDA coverage was >80%[37]. The overall TF prevalence was reduced from 27.3% at baseline
to 9.4% one year after the third MDA round, and infection prevalence was reduced from
>20% in 1-9-year olds to<10% in the fourth year. The resurgence of infection prevalence dur-
ing our study may have been due to a combination of insufficient MDA coverage and interac-
tion with untreated neighboring communities. Community members are mainly pastoralists
and often away from their homes during the day. These results highlight the need for high
MDA coverage to effectively bring C. trachomatis prevalence under control. However, the sus-
tained reduction in TP prevalence following MDA may be promising in terms of reducing
scarring risk.
This study has several limitations. Only the left eye was examined and sampled throughout
the longitudinal study as it was not feasible to process samples from both eyes at all time-
points. There were changes in the detection method for C. trachomatis between baseline and
all other time-points, which could have introduced some variability, however the agreement
between methods was good and due to the large sample size and high number of time-points
the interpretation of the results is not expected to be affected. As with any longitudinal study
there was some loss to follow-up. In this study we found that the children for whom we were
unable to collect outcome data were slightly older and more likely to be male. Although this
moderate difference between those seen and not seen could potentially introduce some bias,
the cohort size remained substantial to the end, and despite the loss to follow-up we were able
draw clear conclusions. It is possible that MDA treatment could have had a beneficial effect
against scarring progression through the known anti-inflammatory properties of azithromy-
cin, however further investigation of this was outside the scope of the current study. The three-
monthly spacing of observations are too far apart to be able to estimate the duration of disease
and infection episodes. The study was designed to investigate individual level risk of progres-
sion in scarring and was of sufficient size to demonstrate this. However, it was not designed to
provide community level estimates of the risk of progression, which would require a much
larger number of communities and many more to children.
Conclusion
Progressive scarring trachoma was strongly associated with papillary inflammation in this lon-
gitudinal study. C. trachomatis infection was no longer associated with scarring progression
after adjustment for TP, suggesting that the effect of infection is mediated through TP, and
that other factors contributing to TP in addition to C. trachomatis infection are important
determinants of disease progression. Further research is required to understand what these
factors are; they might include other ocular or non-ocular infections, genetic variation in host
immune responses or environmental factors. Females were at greater risk of C. trachomatis
infection, clinical inflammation and scarring progression. The addition of TP as an indicator
for trachoma control programs might provide a more accurate marker for the risk of disease
progression and of the need for future trichiasis interventions, which are likely to be needed
for many years to come in this community.
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S1 Fig. Histogram showing the number of time-points at which participants were seen.
Data are shown for the 448 participants with outcome data.
(TIF)
S2 Fig. The prevalence of C. trachomatis infection and clinical signs at each time-point.
Data are shown for the 448 individuals with outcome data, split by village. Red vertical lines
indicate MDA treatment. The red dashed vertical line in village C indicates treatment given
with residual disease
(TIF)
S3 Fig. The association between C. trachomatis infection and clinical signs at each
time-point. TF is shown in blue and TP in red. Odds ratios with 95% confidence intervals
are plotted. The grey vertical lines indicate MDA treatment given to all three study vil-
lages. The grey dashed vertical line indicates treatment given to one village with residual
disease. The OR for TP at time-point 5 is missing as there was insufficient data to generate
a result.
(TIF)
S1 Table. Univariable logistic regression models for scarring progression. These include; a)
incident scarring and b) increase in pre-existing scarring, in individuals with (a) no scarring at
baseline or (b) some scarring at baseline. Univariate associations between scarring and infec-
tion, TF and TP were adjusted for age at baseline and sex.
(DOCX)
S2 Table. Multivariable logistic regression models for scarring progression. These include;
a) incident scarring and b) increase in pre-existing scarring, in individuals with (a) no scarring
at baseline or (b) some scarring at baseline.
(DOCX)
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